David Holland
Optometrist · Hagerstown, MDNPI 1134417025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,322, 3.7 times the $353 reported in 2019. Among optometrist clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$981
- Mallinckrodt Hospital Products Inc.$596
- Tarsus Pharmaceuticals, Inc.$586
- AbbVie$544
- Alcon$454
- Oyster Point Pharma, Inc.$177
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,57498%
- Education$1162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 54 | $981 |
| Mallinckrodt Hospital Products Inc. | 28 | $596 |
| Tarsus Pharmaceuticals, Inc. | 16 | $586 |
| AbbVie(2 entities) | 21 | $544 |
| Alcon | 16 | $454 |
| Oyster Point Pharma, Inc. | 8 | $177 |
| Bausch & Lomb Americas Inc. | 10 | $177 |
| ANI Pharmaceuticals, Inc. | 5 | $159 |
| NEW World Medical,inc. | 1 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $144 |
| Harrow Eye, LLC | 5 | $122 |
| Novartis | 7 | $119 |
| Amgen(2 entities) | 4 | $96 |
| Rxsight Inc | 1 | $95 |
| Dompe US, Inc. | 3 | $91 |
| Thea Pharma Inc. | 3 | $67 |
| Johnson & Johnson Vision Care, Inc. | 2 | $32 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Coopervision Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$228
- XDEMVY$122
- Precision 1$115
How this compares
$4,690 in reported general payments places this provider in the 90th percentile of 790 optometrist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 39 | $72,562 |
| LumiganBimatoprost | 110 | $65,495 |
| RestasisCyclosporine | 43 | $55,667 |
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $38,115 |
| VyzultaLatanoprostene Bunod | 57 | $32,345 |
| CequaCyclosporine | 20 | $16,858 |
| RhopressaNetarsudil Mesylate | 17 | $13,320 |
| Cyclosporine | 21 | $10,837 |
| Alphagan PBrimonidine Tartrate | 13 | $9,955 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $8,876 |
| Latanoprost | 567 | $8,018 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $6,024 |
| Timolol Maleate | 205 | $5,793 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 203 | $4,772 |
| Prednisolone Acetate | 115 | $3,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $544 | $139,992189 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $586 | $72,56239 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $20 | $51,43568 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $177 | $32,34557 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $981 | $16,85820 claims |
| AlconSimbrinza | $454 | $6,02419 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $144 | $2,27720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 optometrist providers in Maryland.
Other optometrist in Hagerstown
- Rose WoodHagerstown$6K
- Lauren WoodHagerstown$4K
- Susan LathropFulton$337K
- Timothy EarleyOakland$276K
- Padmini NathanFrederick$199K
- Alan GlazierRockville$87K
- Andrew MorgensternBethesda$62K
- Devin SasserSilver Spring$40K
- Rizwana IqbalEllicott City$34K
- Brian WoolfPasadena$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.